From the smallest biotech to the biggest pharmaceutical stock, The Motley Fool's Market Check-Up covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.
In this segment from Monday's episode, health-care analyst David Williamson takes a look at Novartis (NVS 2.27%)and its announcement that it will be selling off its blood-borne pathogen diagnostics business to the Barcelona-based company Grifols for $1.7 billion. David takes a look at how this move works into the company's broader strategy, why he thinks it was a great sale for Novartis, and what he thinks of the stock going forward.
Follow David on Twitter @MotleyDavid.
